Mazur Named To Fibrocell Science Board
April 7, 2010 (FinancialWire) — Fibrocell Science, Inc. (OTCBB: FCSC), a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications, has appointed Marc B. Mazur to its board of directors.
Mazur is the chairman of Elsworthy Capital Management Ltd., a London-based European equity hedge fund. Most recently, he was the CEO of Brevan Howard U.S. Asset Management, the U.S. arm of London-based Brevan Howard, Europe's largest hedge fund.
Prior to joining Brevan Howard, Mazur had been a senior advisor to both Tsinghua Venture Capital Co. (a subsidiary of Tsinghua Holdings, the investment arm of Tsinghua University in Beijing) and Think Equity Partners LLC, a San Francisco investment bank focusing on emerging growth companies in biotechnology, software and greentech.
Pennsylvania-based Fibrocell Science is a biotechnology company focused on developing regenerative fibroblast cell therapy for aesthetic, medical and scientific applications.
(For more “c-level” articles go to http://www.financialwire.net/?s=clvloy)
(For more biomedical, biotech and/or pharmaceutical related articles go to http://www.financialwire.net/?s=biomedphrm)
FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
[clvloy] [biomedphrm]
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
